Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating restated by research analysts at BMO Capital Markets in a report released on Tuesday. They currently have a $142.00 price target on the medical equipment provider’s stock. BMO Capital Markets’ target price points to a potential upside of 25.07% from the company’s previous close.

Several other equities analysts have also recently issued reports on the stock. Deutsche Bank raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a research note on Tuesday, November 14th. Zacks Investment Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Edward Jones raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Royal Bank of Canada dropped their target price on shares of Zimmer Biomet to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 7th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $134.05.

Zimmer Biomet (ZBH) traded up $0.03 during trading on Tuesday, reaching $113.54. 1,594,403 shares of the company’s stock traded hands, compared to its average volume of 1,356,405. The firm has a market cap of $22,956.40, a PE ratio of 14.05, a price-to-earnings-growth ratio of 1.76 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet has a 52-week low of $100.81 and a 52-week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The firm’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the previous year, the business posted $1.79 EPS. equities research analysts anticipate that Zimmer Biomet will post 8.03 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of ZBH. Swiss National Bank bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $32,205,000. Huntington National Bank increased its stake in shares of Zimmer Biomet by 23.4% in the 3rd quarter. Huntington National Bank now owns 10,033 shares of the medical equipment provider’s stock valued at $1,305,000 after acquiring an additional 1,905 shares during the last quarter. Stack Financial Management Inc increased its stake in shares of Zimmer Biomet by 0.5% in the 3rd quarter. Stack Financial Management Inc now owns 67,419 shares of the medical equipment provider’s stock valued at $8,766,000 after acquiring an additional 340 shares during the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $3,273,000. Finally, Focused Investors LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $92,741,000. 86.24% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/12/bmo-capital-markets-reaffirms-buy-rating-for-zimmer-biomet-zbh.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.